Not recruiting

Study on the Effects of KBP-336 and Paracetamol for Obese Patients with Knee Osteoarthritis

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called KBP-336 for individuals who are both obese and have osteoarthritis of the knee. Osteoarthritis is a condition that causes pain and stiffness in the joints, and it is common in the knees. Obesity can worsen the symptoms of osteoarthritis, making it more challenging to manage. The treatment being tested, KBP-336, is given as an injection and is being evaluated to see if it can help reduce body weight and knee pain when used alongside diet and exercise.

The purpose of this study is to assess how effective and safe KBP-336 is compared to a placebo. Participants in the study will receive either the new treatment or a placebo, and their progress will be monitored over a period of time. The study will look at changes in body weight and knee pain to determine the treatment's effectiveness. Participants will be asked to follow a specific diet and exercise plan during the study.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The study aims to provide valuable information on whether KBP-336 can be a helpful addition to diet and exercise for managing weight and knee pain in people with obesity and osteoarthritis of the knee. The results of this study could lead to new treatment options for individuals facing these health challenges.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, participants will be required to provide written informed consent, confirming their understanding of the study material and willingness to comply with study requirements.
Step 2
Baseline assessment
Participants will undergo a baseline assessment, which includes a physical examination, vital signs check, and laboratory tests to ensure good health. This assessment will also confirm the diagnosis of knee osteoarthritis and obesity.
Step 3
Medication withdrawal
Participants must withdraw from any current pain medications, except for the allowed rescue medication, which is a maximum of 4000 mg of paracetamol per day.
Step 4
Randomization and treatment
Participants will be randomly assigned to receive either the study medication KBP-336 or a placebo. KBP-336 is administered as a solution for injection under the skin (subcutaneous).
The frequency and dosage of KBP-336 will be determined by the study protocol and communicated to participants during the trial.
Step 5
Diet and exercise program
Participants will follow a diet and exercise program designed to support weight loss and improve knee function. This program is an essential part of the study.
Step 6
Regular follow-up visits
Participants will attend regular follow-up visits to monitor their health, body weight, and knee pain. These visits will include assessments using the WOMAC pain scale, which measures pain, stiffness, and physical function in the knee.
Step 7
End of treatment assessment
At the end of the treatment period, which is approximately 183 days, participants will undergo a final assessment. This will include measurements of body weight, knee pain, and overall health.
Step 8
Study completion
Upon completion of the study, participants will receive information about the study results and any further steps if necessary.

Who can join the trial?

10 criteria

The participant must be able to read and understand the study materials and provide written consent to participate.
The participant must be willing to stop using any pain medication, such as Opioids (strong painkillers), Non-Steroidal Anti-Inflammatories (NSAIDs) (like ibuprofen, except for low-dose aspirin for blood clot prevention), COX-2 inhibitors (a type of pain reliever), Topical medication (creams or gels applied to the skin), and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) (a type of antidepressant like Duloxetine). They can only use the allowed rescue medication, which is a maximum of 4000 mg of paracetamol per day.
The participant must be willing and able to follow the study requirements and instructions.
The participant must have a diagnosis of Osteoarthritis (OA) in the knee, confirmed by specific criteria, with symptoms present for at least 3 months before the study starts.
The participant must have a specific grade (2 or 3) of knee OA, determined by an X-ray taken during screening or a recent X-ray that meets the study's requirements.
The participant must be at least 45 years old, regardless of gender.
The participant must have a Body Mass Index (BMI) of 30 kg/m² or higher. BMI is a measure of body fat based on height and weight.
The participant must be in good health, meaning no significant medical issues or abnormal findings during a physical exam, vital signs check, heart test (ECG), and lab results, as judged by the study doctor.
The participant must have experienced intolerance or insufficient pain relief with standard treatments for knee OA, such as physiotherapy, paracetamol, NSAIDs, short-term opioid use, or injections of hyaluronic acid or corticosteroids, as judged by the study doctor.
The participant must have a specific level of pain in the knee, measured by a WOMAC pain subscale score of 20 or higher on a scale of 0 to 50, both at the start of the study and during screening.

Who cannot join the trial?

3 criteria

Patients who do not have knee osteoarthritis or obesity cannot participate.
Patients who are not within the specified age range cannot participate.
Patients who are part of a vulnerable population cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Dc-Med Michal Kowalski sp.k.
Swidnica, Poland
Verified
Medical Plus s.r.o.
Uherske Hradiste, Czechia
Verified
Sanos A/S
Gandrup, Denmark

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

KBP-336 is a medication being tested to see if it can help people who are overweight and have knee pain due to osteoarthritis. The study is looking at how well this medication works when combined with a healthy diet and regular exercise. The goal is to find out if KBP-336 can help reduce body weight and relieve knee pain in people with this condition. The medication is being compared to a placebo, which is a substance with no active ingredients, to see if it has a real effect on weight loss and pain relief.

What is already known about the treatment

KBP-336 – KBP-336 is administered orally in the form of a pill and is currently being studied in clinical trials to assess its effectiveness and safety. It is being investigated for its potential to help with weight loss and reduce pain in individuals suffering from knee osteoarthritis, particularly those who are also dealing with obesity. The medication works by targeting specific pathways in the body that are involved in weight regulation and inflammation, which may help alleviate pain and promote weight loss. KBP-336 is classified as a therapeutic agent aimed at managing obesity and osteoarthritis symptoms.

Investigated diseases

Knee Osteoarthritis
Knee osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage in the knee joint. As the cartilage wears away, bones begin to rub against each other, causing pain, swelling, and reduced motion in the joint. Over time, the joint may become stiffer and more painful, especially after periods of inactivity or excessive use. The condition can lead to the formation of bone spurs and a decrease in the joint space. It often progresses slowly, with symptoms worsening over years. Factors such as age, weight, and previous joint injuries can influence its progression.
Obesity
Obesity is a condition characterized by excessive body fat accumulation that may impair health. It develops when calorie intake consistently exceeds calorie expenditure, leading to an energy imbalance. Over time, this excess energy is stored as fat, resulting in increased body weight. Obesity can lead to changes in body composition, including increased fat mass and altered distribution of fat in the body. It is often associated with metabolic changes and can affect various bodily systems. The progression of obesity can be influenced by genetic, environmental, and lifestyle factors.